Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 19, 2000

View Archived Issues

Maxygen and Scripps to collaborate in developing HIV vaccines

CGA-137053, a novel compound that blocks HIV replication by targeting the Tat protein

Phase II NeuroCell-PD trial for Parkinson's disease extended

Novel family of MTP inhibitors discovered at Janssen possess lipid-lowering properties

Wyeth-Ayerst obtains Alzheimer's drug discovery-related license

New HIV treatment option approved by FDA

Isoflavone-based bone resorption inhibitors presented by Chiesi in Bologna this week

Banyu's J-112287: a potent, selective and orally active ETA receptor antagonist

Highly potent motilin antagonists reported by Chugai

Antithrombotic development candidates profiled in Bologna by Mochida

Guanidine-based Na+/H+ inhibitors synthesized and tested at Sumitomo

Therapeutically useful M3/5-HT4 antagonists patented by major French lab

Newly issued patent covers series of guanylate cyclase activators designed by Aventis

SK reveals orally active compounds for depression which inhibit MAO

Sanofi-Synthelabo discloses synthesis and use of new alpha-azacyclomethylquinolines

ICAAC news: Janssen discovers novel fusion inhibitor with picomolar anti-RSV activity

Alphav integrin receptor antagonists claimed by Merck for inhibiting bone resorption

Novel chemokine receptor modulators revealed by Millennium

Research at Sanofi-Synthelabo leads to discovery of promising selective CB1 antagonist

Pseudo-proline-containing ciclosporin derivatives useful as prodrugs

Takeda presents newest antifungal candidates this week in Toronto

Combination 2ME2 and Taxotere trial begins

Glaxo Wellcome seeks new indication for Relenza

MetaPhore receives NIH grant for the study of novel pain treatments

Phase I Oncolym study begins for relapsed and refractory B-cell lymphoma

Almirall Prodesfarma commences launch of new triptan for migraine

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...